Characterization of Gut and Tongue Coating Microbiota in Patients With Diminished Ovarian Reserve
Condition(s) studied
Investigational drug(s) / intervention(s)
gut microbiota: Fresh fecal samples were collected from patients during the non-menstrual period and subjected to 16S rDNA sequencing.
tongue coating microbiota: Tongue coating samples were collected under fasting conditions between 6:00-9:00 AM on the same day as fecal specimen collection and subjected to 16S rDNA sequencing.
tongue picture: Tongue images were captured under fasting conditions between 6:00-9:00 AM on the same morning as fecal specimen collection.
Study summary
The goal of this observational study is to investigate the distinct tongue manifestation characteristics in patients with diminished ovarian reserve (DOR) compared to healthy individuals, and to clarify the features of tongue coating microbiota, gut microbiota, and their interrelationships in DOR patients. The main question it aims to answer is:
Whether there are significant differences in tongue manifestations, tongue coating microbiota, and gut microbiota characteristics between DOR patients and healthy populations; Whether associations exist between tongue coating microbiota and gut microbiota in DOR patients; Whether the pathogenesis of DOR may influence estrogen metabolism through alterations in oral and gut microbiota.
Eligibility
Primary outcome measure(s)
- Follicle stimulating hormone — On day 2 or 3 of the menstrual phase during the first menstrual cycle following participant enrollment.
Follicle stimulating hormone in IU/L
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hangzhou TCM Hospital of Zhejiang Chinese Medical University | Hangzhou | Zhejiang | Recruiting |
More Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07124260 on ClinicalTrials.gov ↗ ← All trials in China